## SEQUENCE LISTING

```
<110> Johnson et al.
<120> INHIBITION OF THE MHC CLASS II ANTIGEN PRESENTATION
      PATHWAY AND PRESENTATION TO CD4+ CELLS
<130> 0899-54203 Johnson
<140>
<141>
<150> 60/118,287
<151> 1999-02-02
<160> 7
<170> PatentIn Ver. 2.1
<210> 1
<211> 600
<212> DNA
<213> Cytomegalovirus
<400> 1
teageacaeg aaaaaeegea teeacateat agacaagtta eagteeaeag teacataeae 60
gataaacaat accaacaggg taatgtttat ggagtaaaac actattgtcc aggccacatg 120
cgtgtatgac ttccgcacca tcccgtactg catgttccac atgtacgcgc tagacgtqta 180
atccactcgc agttcgggga cgcaacgcag ccagatcaca tccccttgca gtaccagacg 240
cagggctage gtetegaaga teggcateae atetaagtte egeaegttee aetttaaega 300
ctccccggga acgaactcca cgtcgtcggc gtgtacgtac aggttctctc ccacgccgcc 360
ataatcggcc ttcggatcga agacgaaccg actcatgttg cccacgatgc tcccccgagc 420
aaacaacttg ccgttgtcaa tgtagcaccg gttgtcctcg atttgaaacc agggatgctt 480
ggeogtggac ttccagggcc ggagcgctc ttccccggct ttagtgattc catcggcag 540
gcggatcaag ggacccatgg aggtccaaag acccacccag gctttccaga gattgttcat 600
<210> 2
<211> 600
<212> DNA
<213> Cytomegalovirus
<220>
<221> CDS
<222> (1)..(600)
<400> 2
atg aac aat ctc tgg aaa gcc tgg gtg ggt ctt tgg acc tcc atg ggt
                                                                   48
Met Asn Asn Leu Trp Lys Ala Trp Val Gly Leu Trp Thr Ser Met Gly
ecc ttg atc ege etg ecc gat gga atc act aaa gee ggg gaa gae geg
                                                                   96
Pro Leu Ile Arg Leu Pro Asp Gly Ile Thr Lys Ala Gly Glu Asp Ala
ctc cgg ccc tgg aaq tcc acg gcc aag cat ccc tgg ttt caa atc gaq
Leu Arg Pro Trp Lys Ser Thr Ala Lys His Pro Trp Phe Gln Ile Glu
                             40
gac aac cgg tgc tac att gac aac ggc aag ttg ttt gct cgg ggg agc
                                                                   192
```

WO 00/46361 PCT/US00/02740

***	0, 100	V-														. 02
Asp	Asn 50	Arg	Cys	Tyr	Ile	Asp 55	Asn	Gly	Lys	Leu	Phe 60	Ala	Arg	Gly	Ser	
						cgg Arg										240
						ctg Leu										288
						aag Lys										336
_				_		gcc Ala	_	_	_	-	_			_		384
			_	_	_	ccc Pro 135	-	_	_		-		_		-	432
		_			_	cag Gln			_			_			_	480
						gtg Val										528
_	_			~ -		gtg Val			~	_		_		_	_	576
	_		ttt Phe			tgc Cys	tga 200									600

<210> 3

<211> 199

<212> PRT

<213> Cytomegalovirus

<400> 3

 Met
 Asn
 Asn
 Leu
 Trp
 Lys
 Ala
 Trp
 Val
 Gly
 Leu
 Trp
 Thr
 Ser
 Met
 Gly

 Pro
 Leu
 Ile
 Pro
 Asp
 Gly
 Ile
 Thr
 Lys
 Ala
 Gly
 Glu
 Asp
 Ala

 Leu
 Arg
 Pro
 Lys
 Ser
 Thr
 Ala
 Lys
 His
 Pro
 Trp
 Phe
 Glu
 Asp
 Ala
 Asp
 Ile
 Glu
 Asp
 Asp
 Asp
 Asp
 Ile
 Asp
 Asp
 Ile
 Ile
 Asp
 Asp
 Ile
 Ile
 Asp
 Asp
 Ile
 Ile

WO 00/46361 PCT/US00/02740

 Pro Ile
 Phe Glu
 Thr
 Leu
 Ala
 Leu
 Arg
 Leu
 Val
 Leu
 Gln
 Gly
 Asp
 Val

 116
 Trp
 Leu
 Arg
 Cys
 Val
 Pro
 Glu
 Leu
 Arg
 Val
 Asp
 Tyr
 Thr
 Ser
 Ser
 Ser
 Ser
 Ser
 Ser
 Ser
 Tyr
 Thr
 Ser
 Ser
 Tyr
 Thr
 Thr
 Thr
 Inchested
 Inchested

<210> 4 <211> 534 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: chimera <220> <221> CDS <222> (1)..(534) <400> 4 atg aaa tto tta gto aac gtt gco ctt gtt ttt atg gto gtg tac att Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile 5 tot tac atc tat gcg cgc ctg ccc gat gga atc act aaa gcc ggg gaa Ser Tyr Ile Tyr Ala Arg Leu Pro Asp Gly Ile Thr Lys Ala Gly Glu 20 gac gcg ctc cgg ccc tgg aag tcc acg gcc aag cat ccc tgg ttt caa Asp Ala Leu Arg Pro Trp Lys Ser Thr Ala Lys His Pro Trp Phe Gln 35 atc gag gac aac cgg tgc tac att gac aac ggc aag ttg ttt gct cgg Ile Glu Asp Asn Arg Cys Tyr Ile Asp Asn Gly Lys Leu Phe Ala Arg ggg agc atc gtg ggc aac atg agt cgg ttc gtc ttc gat ccg aag gcc Gly Ser Ile Val Gly Asn Met Ser Arg Phe Val Phe Asp Pro Lys Ala 65 70 gat tat ggc ggc gtg gga gag aac ctg tac gta cac gcc gac gac gtg Asp Tyr Gly Gly Val Gly Glu Asn Leu Tyr Val His Ala Asp Asp Val 85 90 95

48

144

192

240

110

gtg atg ccg atc ttc gag acg cta gcc ctg cgt ctg gta ctg caa ggg 38 Val Met Pro Ile Phe Glu Thr Leu Ala Leu Arg Leu Val Leu Gln Gly 115 120 125

gag ttc gtt ccc ggg gag tcg tta aag tgg aac gtg cgg aac tta gat Glu Phe Val Pro Gly Glu Ser Leu Lys Trp Asn Val Arg Asn Leu Asp

105

WO 0	0/463	61												PC	CT/US0	0/02740
							gtc Val									432
							atg Met									480
							gag Glu									528
gtg Val	tga															534
<212 <212 <213		RT ctif:	icial iptic				cial	Seqi	ience	e: cl	nime	ra -				
Met 1				5			Ala		10					15		
Ser	Tyr	Ile	Tyr 20	Ala	Arg	Leu	Pro	Asp 25	Gly	Ile	Thr	Lys	Ala 30	Gly	Glu	
Asp	Ala	Leu 35	Arg	Pro	Trp	Lys	Ser 40	Thr	Ala	Lys	His	Pro 45	Trp	Phe	Gln	
Ile	Glu 50	Asp	Asn	Arg	Cys	Tyr 55	Ile	Asp	Asn	Gly	Lys 60	Leu	Phe	Ala	Arg	
Gly 65	Ser	Ile	Val	Gly	Asn 70	Met	Ser	Arg	Phe	Val 75	Phe	Asp	Pro	Lys	Ala 80	
Asp	Tyr	Gly	Gly	Val 85	Gly	Glu	Asn	Leu	Tyr 90	Val	His	Ala	Asp	Asp 95	Val	
Glu	Phe	Val	Pro 100	Gly	Glu	Ser	Leu	Lys 105	Trp	Asn	Val	Arg	Asn 110	Leu	Asp	
Val	Met	Pro 115	Ile	Phe	Glu	Thr	Leu 120	Ala	Leu	Arg	Leu	Val 125	Leu	Gln	Gly	
Asp	Val 130	Ile	Trp	Leu		Cys 135	Val	Pro	Glu		Arg 140		Asp	Tyr	Thr	
Ser 145	Ser	Ala	Tyr	Met	Trp 150	Asn	Met	Gln	Tyr	Gly 155	Met	Val ·	Gly	Gln	Pro 160	
Glu Val	Leu	Ala	Pro	Glu 165	Asp	Pro	Glu	Asp	Ser 170	Ala	Leu	Leu	Glu	Asp 175	Pro	
<21: <21: <21: <22: <22: <40	0> 3> De	NA rtif: escr:		on o	f Art	ifi¢	cial			ə: O)	ligor	nucle	eotic	de		
cgc	ggat	cca i	tgaad	caato	et ci	ggaa	aagc	c tg	3							33

WO 00/46361 PCT/US00/02740

## SEQUENCE LISTING

```
<110> Johnson et al.
<120> INHIBITION OF THE MHC CLASS II ANTIGEN PRESENTATION
      PATHWAY AND PRESENTATION TO CD4+ CELLS
<130> 0899-59399
<140>
<141>
<150> US00/02740
<151> 2000-02-02
<150> 60/118,287
<151> 1999-02-02
<160> 7
<170> PatentIn Ver. 2.1
<210> 1
<211> 600
<212> DNA
<213> Cytomegalovirus
<400> 1
teageacaeg aaaaacegea teeacateat agacaagtta eagteeacag teacatacae 60
gataaacaat accaacaggg taatgtttat ggagtaaaac actattgtcc aggccacatg 120
cgtgtatgac ttccgcacca tcccgtactg catgttccac atgtacgcgc tagacgtgta 180
atccactcgc agttcgggga cgcaacgcag ccagatcaca tccccttgca gtaccagacg 240
cagggctage gtetegaaga teggeateae atetaagtte egeaegttee aetttaaega 300
ctccccggga acquaetcca cgtcgtcggc gtgtacgtac aggttetete ccacgccgcc 360
ataatcggcc ttcggatcga agacgaaccg actcatgttg cccacgatgc tcccccgagc 420
aaacaacttg ccgttgtcaa tgtagcaccg gttgtcctcg atttgaaacc agggatgctt 480
ggccgtggac ttccagggcc ggagcgcgtc ttccccggct ttagtgattc catcgggcag 540
gcggatcaag ggacccatgg aggtccaaag acccacccag gctttccaga gattgttcat 600
<210> 2
<211> 600
<212> DNA
<213> cytomegalovirus
<220>
<221> CDS
<222> (1)..(600)
<400> 2
atg aac aat ctc tgg aaa gcc tgg gtg ggt ctt tgg acc tcc atg ggt
Met Asn Asn Leu Trp Lys Ala Trp Val Gly Leu Trp Thr Ser Met Gly
                                      10
ccc ttg atc cgc ctg ccc gat gga atc act aaa gcc ggg gaa gac gcg
Pro Leu Ile Arg Leu Pro Asp Gly Ile Thr Lys Ala Gly Glu Asp Ala
                                 25
             20
                                                      30
```

ctc cgg ccc Leu Arg Pro 35		_	-	_					144
gac aac cgg Asp Asn Arg 50	-		_		-	-			192
atc gtg ggc Ile Val Gly 65	-		-				_		240 .
ggc ggc gtg Gly Gly Val							Val G		288
gtt ccc ggg Val Pro Gly		-	Trp A			Leu A	-	-	336
ccg atc ttc Pro Ile Phe 115									384
atc tgg ctg Ile Trp Leu 130									432
gcg tac atg Ala Tyr Met 145									480
cat gtg gcc His Val Ala								u Leu	528
gta ttg ttt Val Leu Phe			Thr V		-	Leu S			576
tgg atg cgg Trp Met Arg 195			tga						600
<210> 3 <211> 199 <212> PRT <213> cytome	egalovir	ıs							
<400> 3 Met Asn Asn 1	Leu Trp	Lys Ala	Trp V	al Gly	Leu Trp	Thr S		et Gly	
Pro Leu Ile	Arg Leu	Pro Asp			Lys Ala	Gly G			
Leu Arg Pro	_	Ser Thr			Pro Trp	Phe G		e Glu	

Asp Asn Arg Cys Tyr Ile Asp Asn Gly Lys Leu Phe Ala Arg Gly Ser 55 Ile Val Gly Asn Met Ser Arg Phe Val Phe Asp Pro Lys Ala Asp Tyr Gly Gly Val Gly Glu Asn Leu Tyr Val His Ala Asp Asp Val Glu Phe 90 Val Pro Gly Glu Ser Leu Lys Trp Asn Val Arg Asn Leu Asp Val Met 105 110 Pro Ile Phe Glu Thr Leu Ala Leu Arg Leu Val Leu Gln Gly Asp Val 120 Ile Trp Leu Arg Cys Val Pro Glu Leu Arg Val Asp Tyr Thr Ser Ser 135 Ala Tyr Met Trp Asn Met Gln Tyr Gly Met Val Arg Lys Ser Tyr Thr 150 155 His Val Ala Trp Thr Ile Val Phe Tyr Ser Ile Asn Ile Thr Leu Leu 165 170 Val Leu Phe Ile Val Tyr Val Thr Val Asp Cys Asn Leu Ser Met Met 180 185 Trp Met Arg Phe Phe Val Cys 195 <210> 4 <211> 534 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence:chimera <220> <221> CDS <222> (1)..(534) <400> 4 atg aaa ttc tta gtc aac gtt gcc ctt gtt ttt atg gtc gtg tac att Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile tct tac atc tat gcg cgc ctg ccc gat gga atc act aaa gcc ggg gaa Ser Tyr Ile Tyr Ala Arg Leu Pro Asp Gly Ile Thr Lys Ala Gly Glu 20 gac gcg ctc cgg ccc tgg aag tcc acg gcc aag cat ccc tgg ttt caa Asp Ala Leu Arg Pro Trp Lys Ser Thr Ala Lys His Pro Trp Phe Gln 35 atc gag gac aac cgg tgc tac att gac aac ggc aag ttg ttt gct cgg 192 Ile Glu Asp Asn Arg Cys Tyr Ile Asp Asn Gly Lys Leu Phe Ala Arg 55 ggg agc atc gtg ggc aac atg agt cgg ttc gtc ttc gat ccg aag gcc Gly Ser Ile Val Gly Asn Met Ser Arg Phe Val Phe Asp Pro Lys Ala 65 70 75

Asp Tyr Gly G	c gtg gg y Val Gl 85									288
gag ttc gtt co Glu Phe Val Pr 10	o Gly Gl									336
gtg atg ccg at Val Met Pro Il 115			eu Āla							384
gat gtg atc to Asp Val Ile Tr 130										432
tct agc gcg ta Ser Ser Ala Ty 145		p Asn Me			/ Met			_		480
gaa ctc gcc co Glu Leu Ala Pr										528
gtg tga Val										534
<210> 5										
<211> 177 <212> PRT <213> Artifici	al Seque	nce								
<212> PRT			ıl Sequ	ience:cl	nimera	à				
<212> PRT <213> Artifici <220> <223> Descript <400> 5 Met Lys Phe Le	ion of A	rtificia		Val Phe			Val		Ile	
<212> PRT <213> Artifici <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty	ion of A u Val As 5 r Ala Ar	rtificia n Val Al	a Leu	Val Phe	e Met	Val	Ala	15		
<212> PRT <213> Artifici <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty Asp Ala Leu Ar	ion of A u Val As 5 r Ala Ar 0	rtificia n Val Al g Leu Pr p Lys Se	a Leu o Asp 25 er Thr	Val Phe 10 Gly Ile	e Met	Val Lys Pro	Ala 30	15 Gly	Glu	
<212> PRT <213> Artificit <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty Asp Ala Leu Ar 35 Ile Glu Asp As	ion of A u Val As r Ala Ar 0 g Pro Tr	rtificia n Val Al g Leu Pr p Lys Se 4 s Tyr Il	a Leu o Asp 25 er Thr	Val Phe 10 Gly Ile Ala Lys	e Met Thr His	Val Lys Pro 45	Ala 30 Trp	15 Gly Phe	Glu Gln	
<212> PRT <213> Artificit <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty Asp Ala Leu Ar 35 Ile Glu Asp As 50 Gly Ser Ile Va	ion of A u Val As 5 r Ala Ar 0 g Pro Tr n Arg Cy 1 Gly As	rtificia n Val Al g Leu Pr p Lys Se 4 s Tyr Il 55 n Met Se	a Leu Co Asp 25 Er Thr Co Le Asp	Val Phe 10 Gly Ile Ala Lys Asn Gly	Met Thr His Lys 60 Phe	Val Lys Pro 45 Leu	Ala 30 Trp Phe	15 Gly Phe Ala	Glu Gln Arg Ala	
<212> PRT <213> Artificit <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty Asp Ala Leu Ar 35 Ile Glu Asp As 50	ion of A  u Val As  r Ala Ar  g Pro Tr  n Arg Cy  l Gly As  7  y Val Gl	rtificia n Val Al g Leu Pr p Lys Se 4 s Tyr Il 55 n Met Se	a Leu CO Asp 25 Er Thr CO Le Asp	Val Phe 10 Gly Ile Ala Lys Asn Gly Phe Val 75 Tyr Val	Met Thr His Lys 60 Phe	Val Lys Pro 45 Leu Asp	Ala 30 Trp Phe Pro	15 Gly Phe Ala Lys	Glu Gln Arg Ala 80	
<212> PRT <213> Artificit <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty Asp Ala Leu Ar 35 Ile Glu Asp As 50 Gly Ser Ile Va 65 Asp Tyr Gly Gl Glu Phe Val Pr	ion of A  u Val As  5 r Ala Ar 0 g Pro Tr n Arg Cy 1 Gly As 7 y Val Gl 85 o Gly Gl	rtificia n Val Al g Leu Pr p Lys Se 4 s Tyr Il 55 n Met Se 0 y Glu As	a Leu  To Asp 25  Thr 10  Le Asp er Arg	Val Phe 10 Gly Ile Ala Lys Asn Gly Phe Val 75 Tyr Val 90	e Met Thr His Lys 60 Phe His	Val Lys Pro 45 Leu Asp	Ala 30 Trp Phe Pro Asp	15 Gly Phe Ala Lys Asp 95	Glu Gln Arg Ala 80 Val	
<212> PRT <213> Artificit <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty Asp Ala Leu Ar 35 Ile Glu Asp As 50 Gly Ser Ile Va 65 Asp Tyr Gly Gl Glu Phe Val Pr 10 Val Met Pro Il	ion of A  u Val As  5 r Ala Ar 0 g Pro Tr n Arg Cy 1 Gly As 7 y Val Gl 85 o Gly Gl 0	rtificia n Val Al g Leu Pr p Lys Se 4 s Tyr Il 55 n Met Se 0 y Glu As	a Leu co Asp 25 er Thr 0 e Asp er Arg sn Leu Lys 105 eu Ala	Val Phe 10 Gly Ile Ala Lys Asn Gly Phe Val 75 Tyr Val 90 Trp Asr	e Met Thr His Lys 60 Phe His	Val Lys Pro 45 Leu Asp Ala	Ala 30 Trp Phe Pro Asp Asn 110	15 Gly Phe Ala Lys Asp 95 Leu	Glu Gln Arg Ala 80 Val	
<212> PRT <213> Artificit <220> <223> Descript <400> 5 Met Lys Phe Le 1 Ser Tyr Ile Ty 2 Asp Ala Leu Ar 35 Ile Glu Asp As 50 Gly Ser Ile Va 65 Asp Tyr Gly Gl Glu Phe Val Pr	ion of A u Val As 5 r Ala Ar 0 g Pro Tr n Arg Cy 1 Gly As 7 y Val Gl 85 o Gly Gl 0 e Phe Gl	rtifician Val Al g Leu Pr Pr Lys Se Ar S Tyr Il S S S S Tyr Il S S S S S S S S S S S S S S S S S S	a Leu Co Asp 25 Er Thr Co Le Asp Er Arg En Leu Lys 105 Eu Ala	Val Phe 10 Gly Ile Ala Lys Asn Gly Phe Val 75 Tyr Val 90 Trp Asr	Met Thr His His 60 Phe His Val	Val Lys Pro 45 Leu Asp Ala Arg	Ala 30 Trp Phe Pro Asp Asn 110 Leu	15 Gly Phe Ala Lys Asp 95 Leu Gln	Glu Gln Arg Ala 80 Val Asp Gly	

33

Glu Leu Ala Pro Glu Asp Pro Glu Asp Ser Ala Leu Leu Glu Asp Pro

170

165

cgtgaattcg acatgacaca cgtaatgggt act

•

Val